10-Q: Dianthus Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Dianthus Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its clinical trials and providing an update on its financial position.

Summary

• Dianthus Therapeutics, a clinical-stage biotechnology company, announced its financial results for the first quarter ended March 31, 2025.
• The company is focused on developing next-generation complement therapeutics for autoimmune and inflammatory diseases, with its lead product candidate, DNTH103, currently in midto late-stage clinical trials.
• Dianthus is enrolling patients in three clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
• The MaGic trial, a Phase 2 study in gMG, completed enrollment in May 2025 with 65 patients, and top-line results are expected in September 2025.
• The CAPTIVATE trial, a Phase 3 trial in CIDP, anticipates completing an interim responder analysis of the first 40 participants in Part A in the second half of 2026.
• The MoMeNtum trial, a Phase 2 study in MMN, anticipates initial top-line results to be available in the second half of 2026.
• For the three months ended March 31, 2025, Dianthus reported total revenues of $1.2 million, primarily from license revenue related to the Tenacia Agreements.
• Research and development expenses were $27.0 million, and general and administrative expenses were $7.3 million for the same period.
• The net loss for the quarter was $29.5 million, or $0.82 per share.
• As of March 31, 2025, Dianthus had cash, cash equivalents, and investments totaling $331.5 million, which is expected to fund operations into the second half of 2027.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress in its clinical trials and has sufficient cash to fund operations for the next two years, it is still incurring significant losses and faces numerous risks and uncertainties.

Positives

• The MaGic trial, a Phase 2 study in gMG, completed enrollment in May 2025 with 65 patients, exceeding the initial target of 60 patients.
• Dianthus has cash, cash equivalents, and investments of $331.5 million as of March 31, 2025, which is expected to fund operations into the second half of 2027.
• The company recognized $1.0 million of revenue upon the achievement of a milestone under the Tenacia Agreements.

Negatives

• Dianthus reported a net loss of $29.5 million, or $0.82 per share, for the three months ended March 31, 2025.
• The company has incurred significant operating losses and negative cash flows from operations since its inception.
• Dianthus expects to continue to incur significant expenses and operating losses for the foreseeable future.

Risks

• The company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including uncertainty of product development and commercialization.
• Dianthus is dependent on its key personnel, consultants, and advisors.
• The company's ability to raise additional financing and comply with government regulations poses risks.
• Uncertainty in the global economy presents significant risks to the business, including inflationary pressures, economic slowdown, and geopolitical developments.
• The successful development of DNTH103 or any future product candidates is highly uncertain.

Future Outlook

Dianthus expects its existing cash, cash equivalents, and investments to fund operations into the second half of 2027 and plans to continue advancing DNTH103 through clinical trials.

Management Comments

• We believe our lead novel and proprietary monoclonal antibody product candidate, DNTH103, has the potential to address a broad array of complement-dependent diseases as currently available therapies and those in development leave room for improvements in efficacy, safety, and/or dosing convenience.

Industry Context

Dianthus is operating in the competitive biotechnology industry, focusing on complement therapeutics for autoimmune and inflammatory diseases, where there is a need for improved efficacy, safety, and dosing convenience compared to existing therapies.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards or benchmarks.
• Without specific comparible companies, projects, and results, a detailed comparison is not possible.

Legal Proceedings

• From time to time, we may be involved in litigation and other legal proceedings arising in the ordinary course of our business.
• We are not currently a party to or aware of any legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition, results of operations or cash flows.

Related Party Transactions

• The Company considers Zenas to be a related party because Tellus BioVentures LLC (Tellus), whose sole member is a significant shareholder in the Company and a member of the board of directors of the Company, is also a significant shareholder in Zenas and serves as Chief Executive Officer and Chairman of the board of directors of Zenas.
• As of March 31, 2025, Tellus and its affiliated entities owned approximately 5 % of the Companys outstanding shares.
• The Company was previously party to the Zenas Agreements, which were assigned to Zenas HK in October 2024.
• After the assignment, the Company entered into the Novation Agreement with Zenas HK and Tenacia, pursuant to which Tenacia replaced Zenas HK as a party to the Zenas Agreements.
• In connection with these agreements, the Company recognized nil and $ 0.9 million of revenue from Zenas within the license revenue related party line item in the unaudited condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2025 and 2024, respectively.
• As of December 31, 2024, the Company recorded a related party receivable of $ 0.8 million on its unaudited condensed consolidated balance sheet for activities related to Zenas.
• In September 2020, Zenas issued 156,848 common shares to the Company in exchange for the Zenas Option.

Stakeholder Impact

• The company's progress in clinical trials and financial stability are important for shareholders.
• Employees are impacted by the company's financial performance and ability to fund research and development.
• Patients with autoimmune and inflammatory diseases are stakeholders in the development of new and effective therapies.
• The company's relationships with suppliers, vendors, and business partners are important for its operations.

Next Steps

• The company will continue to enroll patients in clinical trials for DNTH103 in gMG, CIDP, and MMN.
• Top-line results from the MaGiC trial in gMG are expected in September 2025.
• An interim responder analysis of the CAPTIVATE trial in CIDP is anticipated in the second half of 2026.
• Initial top-line results from the MoMeNtum trial in MMN are expected in the second half of 2026.

Key Dates

Keywords

DNTH103, clinical trials, financial results, biotechnology, complement therapeutics, autoimmune diseases, inflammatory diseases, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy, license revenue, research and development, net loss, cash reserves